A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006

NCT01463098 | Completed Phase 1 Results FDA Drug

• 1 other identifier: E2006-A001-001
• Study Type: interventional
• Target: 122
• Locations: 1 country
• Sites: 2

Brief Summary

Part A: The purpose of this study is to evaluate the safety and tolerability of single oral doses of E2006 administered in the morning to healthy male and female subjects. Part B: The purpose of this study is to evaluate selected pharmacodynamic (PD) parameters (e.g., polysomnographically defined sleep measures) with regard to dose response in subjects with primary insomnia following single oral dosing of E2006 in the evening approximately 30 minutes prior to the sleep period, compared with 10 mg zolpidem and placebo.

Conditions

Insomnia

Outcome Measures

Primary Outcomes (21)

• Part A: Number of Participants With Treatment Emergent Adverse Events (AEs) and Treatment Emergent Serious Adverse Events (SAEs)

  Baseline up to Day 11

• Part A: Number of Participants With Markedly Abnormal Laboratory Parameter Values

  Baseline up to Day 6

• Part A: Number of Participants With Significant Change From Baseline in Vital Sign Values

  Baseline up to Day 11

• Part A: Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Parameter Values

  Baseline up to Day 11

• Part A: Number of Participants With Any Suicidality Assessed Using Columbia-Suicide Severity Rating Scale (C-SSRS)

  The C-SSRS (mapped to Columbia Classification Algorithm of Suicide Assessment \[C-CASA\]) is an interview-based rating scale to systematically assess any suicidality, any suicidal behavior, any suicidal ideation. Any suicidality: emergence of any suicidal ideation or suicidal behavior. Any suicidal behavior: when response is "yes" for any these questions- actual attempt to suicide, engaged in non-suicidal self-injurious behavior, interrupted attempt, aborted attempt, preparatory acts. Any suicidal ideation: when response is "yes" for any of these questions- wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent to suicide. Number of Participants with any suicidality has been reported for this outcome measure.

  Baseline, Day 11

• Part B: Change From Baseline in Latency to Persistent Sleep (LPS) Assessed Using Polysomnography (PSG) Measurement at Day 1

  LPS was the duration of time in minutes from lights off to the first 30 seconds of recording (epoch) of 20 consecutive epochs of non-wakefulness as measured by PSG.

  Baseline, Day 1

• Part B: Change From Baseline in Total Sleep Time (TST) Assessed Using PSG at Day 1

  TST was the duration in minutes including rapid eye movement (REM) sleep plus non-rapid eye movement (NREM) sleep during the time spent in bed.

  Baseline, Day 1

• Part B: Change From Baseline in Sleep Efficiency Assessed Using PSG at Day 1

  Sleep efficiency was defined as the TST divided by the time in bed (minutes) multiplied by 100. TST was the duration in minutes including REM sleep plus NREM sleep during the time spent in bed.

  Baseline, Day 1

• Part B: Change From Baseline in Wake After Sleep Onset (WASO) Assessed Using PSG at Day 1

  WASO was defined as the duration (in minutes) of wakefulness from onset of persistent sleep to lights-on.

  Baseline, Day 1

• Part B: Change From Baseline in Number of Awakenings After Persistent Sleep (NAW) Assessed Using PSG at Day 1

  Number of awakenings was determined from LPS to lights-on. LPS was the duration of time measured from lights off to the first 30 seconds of PSG measurement recording (epoch) of 20 consecutive epochs of non-wake. An awakening was defined as a PSG recording of at least two consecutive wake epochs.

  Baseline, Day 1

• Part B: Change From Baseline in Percentage of Each Sleep Stage Duration Assessed Using PSG at Day 1

  Sleep stages included NREM sleep and REM (dreaming) sleep. Non-REM sleep is comprised of the sum of Stage N1 (light sleep), N2 (also fairly light, with sudden increases in brain wave frequency known as sleep spindles) and N3 or slow wave sleep (deep sleep). Sleep was staged in sequential 30-second epochs.

  Baseline, Day 1

• Part B: Change From Baseline in Duration (in Minutes) of Each Sleep Stage Assessed Using PSG at Day 1

  Sleep stages included NREM sleep and REM (dreaming) sleep. Non-REM sleep is comprised of the sum of Stage N1 (light sleep), N2 (also fairly light, with sudden increases in brain wave frequency known as sleep spindles) and N3 or slow wave sleep (deep sleep). Sleep was staged in sequential 30-second epochs.

  Baseline, Day 1

• Part B: Change From Baseline in Mean Total Number of Shift in Sleep Stages Assessed Using PSG at Day 1

  Sleep stages included NREM sleep and REM (dreaming) sleep. Non-REM sleep is comprised of the sum of Stage N1 (light sleep), N2 (also fairly light, with sudden increases in brain wave frequency known as sleep spindles) and N3 or slow wave sleep (deep sleep). Sleep was staged in sequential 30-second epochs.

  Baseline, Day 1

• Part B: Change From Day 1 in Waketime Questionnaire Parameters: How Long Did You Sleep Last Night at Day 6

  Participants were asked to answer the following question using Waketime Questionnaire: How long did you sleep last night, number of awakening after falling asleep, time to fall asleep last night, time spent awake after falling asleep, rate quality of your sleep (using Likert scale, ranged from 0 = very sound or restful, to 4 = very restless where lower score indicates better outcome). The primary purpose of the Waketime Questionnaire was to confirm anticipated reports of poor sleep. In this outcome measure, data for question "How long did you sleep last night" has been reported.

  Day 1, Day 6

• Part B: Change From Day 1 in Waketime Questionnaire Parameters: Time to Fall Asleep Last Night at Day 6

  Participants were asked to answer the following question using Waketime Questionnaire: How long did you sleep last night, number of awakening after falling asleep, time to fall asleep last night, time spent awake after falling asleep, rate quality of your sleep (using Likert scale, ranged from 0 = very sound or restful, to 4 = very restless where lower score indicates better outcome). The primary purpose of the Waketime Questionnaire was to confirm anticipated reports of poor sleep. In this outcome measure, data for question "Time to fall asleep last night" has been reported.

  Day 1, Day 6

• Part B: Change From Day 1 in Waketime Questionnaire Parameters: Number of Awakening After Falling Asleep at Day 6

  Participants were asked to answer the following question using Waketime Questionnaire: How long did you sleep last night, number of awakening after falling asleep, time to fall asleep last night, time spent awake after falling asleep, rate quality of your sleep (using Likert scale, ranged from 0 = very sound or restful, to 4 = very restless where lower score indicates better outcome). The primary purpose of the Waketime Questionnaire was to confirm anticipated reports of poor sleep. In this outcome measure, data for question "Number of awakening after falling asleep" has been reported.

  Day 1, Day 6

• Part B: Change From Day 1 in Waketime Questionnaire Parameters: Time Spent Awake After Falling Asleep at Day 6

  Participants were asked to answer the following question using Waketime Questionnaire: How long did you sleep last night, number of awakening after falling asleep, time to fall asleep last night, time spent awake after falling asleep, rate quality of your sleep (using Likert scale, ranged from 0 = very sound or restful, to 4 = very restless where lower score indicates better outcome). The primary purpose of the Waketime Questionnaire was to confirm anticipated reports of poor sleep. In this outcome measure, data for question "Time spent awake after falling asleep" has been reported.

  Day 1, Day 6

• Part B: Change From Day 1 in Waketime Questionnaire Parameters: Rate Quality of Your Sleep at Day 6

  Participants were asked to answer the following question using Waketime Questionnaire: How long did you sleep last night, number of awakening after falling asleep, time to fall asleep last night, time spent awake after falling asleep, rate quality of your sleep (using Likert scale, ranged from 0 = very sound or restful, to 4 = very restless where lower score indicates better outcome). The primary purpose of the Waketime Questionnaire was to confirm anticipated reports of poor sleep. In this outcome measure, data for question "Rate quality of your sleep" has been reported.

  Day 1, Day 6

• Part B: Change From Day 1 (Pre-dose) in Digit Symbol Substitution Test (DSST) Score at Day 6

  DSST is a cognitive test designed to assess psychomotor speed of performance requiring visual perception, spatial decision-making, and motor skills. It consists of 133 digits and requires the participant to substitute each digit with a simple symbol in a 90-second period. Each correct symbol is counted, and the total score ranges from 0 (less than cognitive functioning) to 133 (greater than cognitive functioning) as a description of DSST. An increase in score represents an improvement in an integrated measure of cognitive function.

  Day 1 (Pre-dose), Day 6

• Part B: Change From Day 1 (Pre-dose) in Number of Lapses of Greater Than (>) 500- Milliseconds (Msec) Assessed by Psychomotor Vigilance Test (PVT) at Day 6

  PVT, a computer-based test, is a chronometric measure of an individual's reaction to specified small changes in a labile environment. Participants were instructed to respond to a digital signal on a computer terminal by pressing a key. Errors of omission and commission are recorded. When a participant did not respond to the PVT signal within 500 msec, it was termed a lapse. The higher the number of lapses the greater the impairment.

  Day 1 (Pre-dose), Day 6

• Part B: Change From Day 1 (Pre-dose) in Score on Karolinska Sleepiness Scale (KSS) at Day 6

  KSS is a 9-point scale, on which the participant has to mark his or her sleepiness during the previous 10 minutes. The scale ranges from 1, which indicates "extremely alert", to 9, which indicates "extremely sleepy, can't stay awake". Higher numbers indicating sleepier and lower numbers more alert.

  Day 1 (Pre-dose), Day 6

Secondary Outcomes (23)

• Part A: Maximum Plasma Concentration (Cmax) of E2006

  Day 1: Pre-dose, up to 240 hours post-dose

• Part A: Time to Reach Maximum Plasma Concentration (Tmax) of E2006

  Day 1: Pre-dose, up to 240 hours post-dose

• Part A: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC0-24) of E2006

  Day 1: Pre-dose, up to 240 hours post-dose

• Part A: Area Under the Plasma Concentration-time Curve From Time Zero to t Hours (AUC0-t) of E2006

  Day 1: Pre-dose, up to 240 hours post-dose

• Part A: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of E2006

  Day 1: Pre-dose, up to 240 hours post-dose

Study Arms (14)

Part A: E2006 1.0 mg

EXPERIMENTAL

Drug: E2006 1.0 mg

Part A: E2006 2.5 mg

EXPERIMENTAL

Drug: E2006 2.5 mg

Part A: E2006 5.0 mg

EXPERIMENTAL

Drug: E2006 5.0 mg

Part A: E2006 10.0 mg

EXPERIMENTAL

Drug: E2006 10.0 mg

Part A: E2006 25.0 mg

EXPERIMENTAL

Drug: E2006 25.0 mg

Part A: E2006 50.0 mg

EXPERIMENTAL

Drug: E2006 50.0 mg

Part A: E2006 100 mg

EXPERIMENTAL

Drug: E2006 100 mg

Part A: E2006 200 mg

EXPERIMENTAL

Drug: E2006 200 mg

Part B: Zolpidem 10 mg

EXPERIMENTAL

Drug: Zolpidem 10 mg

Part B: E2006 Matched Placebo or Zolpidem Matched Placebo

EXPERIMENTAL

Drug: E2006 Matched Placebo or Zolpidem Matched Placebo

Part A: E2006 Matched Placebo

EXPERIMENTAL

Drug: E2006 Matched Placebo

Part B: E2006 2.5 mg

EXPERIMENTAL

Drug: E2006 2.5 mg

Part B: E2006 10 mg

EXPERIMENTAL

Drug: E2006 10.0 mg

Part B: E2006 25 mg

EXPERIMENTAL

Drug: E2006 25.0 mg

Interventions

E2006 1.0 mg DRUG

E2006 1.0 mg capsule.

Also known as: Lemborexant

Part A: E2006 1.0 mg

E2006 2.5 mg DRUG

E2006 2.5 mg capsule.

Also known as: Lemborexant

Part A: E2006 2.5 mg; Part B: E2006 2.5 mg

E2006 5.0 mg DRUG

E2006 5.0 mg (2 capsules of 2.5 mg each).

Also known as: Lemborexant

Part A: E2006 5.0 mg

E2006 100 mg DRUG

E2006 100 mg (2 capsules of 50 mg each).

Also known as: Lemborexant

Part A: E2006 100 mg

E2006 25.0 mg DRUG

E2006 25.0 mg (2 capsules of 10 mg each and 2 capsules of 2.5 mg each).

Also known as: Lemborexant

Part A: E2006 25.0 mg; Part B: E2006 25 mg

E2006 50.0 mg DRUG

E2006 50.0 mg capsule.

Also known as: Lemborexant

Part A: E2006 50.0 mg

E2006 200 mg DRUG

E2006 200 mg (4 capsules of 50 mg each).

Also known as: Lemborexant

Part A: E2006 200 mg

Zolpidem 10 mg DRUG

Zolpidem 10 mg immediate release tablet.

Part B: Zolpidem 10 mg

E2006 Matched Placebo or Zolpidem Matched Placebo DRUG

E2006-matched placebo capsules or zolpidem-matched placebo tablets.

Part B: E2006 Matched Placebo or Zolpidem Matched Placebo

E2006 Matched Placebo DRUG

E2006-matched placebo capsule.

Part A: E2006 Matched Placebo

Eligibility Criteria

• Age: 18 Years - 64 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy Subjects:
• With habitual time in bed \> 7 hours, with lights out 2200 to 2400 and lights on 0600 to 0800
• Who report typical sleep latency of \</= 30 minutes
• With typical total sleep time (TST) \>/= 420 minutes
• Primary Insomnia Subjects:
• Otherwise healthy adult male and female subjects with a diagnosis of primary insomnia (as defined by the Diagnostic and Statistical Manual of Mental Disorders-IV-Text Revision \[DSM-IV-TR\]) present at the time of Screening for at least 3 months
• With a score of \> 15 on the Insomnia Severity Index (ISI) at Screening
• Who report taking \>/= 30 minutes to fall asleep on at least 3 nights per week for the past month
• Who report 6.5 hours sleep or less on at least 3 nights per week for the past month
• With mean latency to persistent sleep (LPS) on both baseline nights of \>/= 20 minutes with neither night \< 15 minutes
• With mean wake after sleep onset (WASO) \>/= 20 minutes on both baseline nights, with neither night \< 15 minutes or mean TST \> 420 minutes

You may not qualify if:

• With a current history of sleep disorders (e.g., obstructive sleep apnea, restless leg syndrome \[RLS\], narcolepsy, or circadian rhythm disorder) other than primary insomnia (for Part B)
• Subjects with any clinically abnormal symptom or organ impairment found in medical history, symptoms/signs, vital signs, ECG finding, or laboratory test results which require medical treatment
• All females must be of non-childbearing potential
• With a known history of significant neurological or serious psychiatric illness

Sponsors & Collaborators

• Eisai Inc.: lead

Study Sites (2)

Clinilabs, Inc.

New York, New York, 10019, United States

Location

Community Research

Cincinnati, Ohio, United States

Location

MeSH Terms

Conditions

Sleep Initiation and Maintenance Disorders

Interventions

lemborexant; Zolpidem

Condition Hierarchy (Ancestors)

Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Nervous System Diseases; Mental Disorders

Intervention Hierarchy (Ancestors)

Pyridines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Results Point of Contact

• Title: Eisai Medical Information
• Organization: Eisai Inc.

esi_medinfo@eisai.com

+1-888-274-2378

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 26, 2011
• First Posted: November 1, 2011
• Study Start: October 5, 2011
• Primary Completion: August 11, 2012
• Study Completion: August 11, 2012
• Last Updated: January 18, 2020
• Results First Posted: January 18, 2020

Record last verified: 2013-03

Locations

US (2)